UNSPSC 51162711: Erdosteine

This classification denotes a mucolytic agent with the molecular formula C8H11NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 76J0853EKA, chemically known as acetic acid, ((2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl)thio)- but more generally known as erdosteine, which bears US NIH Compound Identifier 65632. European Medicines Agency schedules Erdosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06595MIG.

UNSPSC 51162711 Erdosteine, a Commodity code, covers pharmaceutical products and related services procured by state and local health and corrections agencies. State and local governments are buying parenteral nutrition solutions, intravenous products, and other injectable pharmaceuticals under this code, along with complementary medical supplies and delivery logistics. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, soliciting parenteral products, services, and equipment—including total parenteral nutrition (TPN), peripheral parenteral nutrition (PPN), intravenous solutions, and controlled substances—for delivery to eight correctional facilities across three regions (West, Central, and East) with responses due October 7, 2026. The scope requires 24-hour turnaround on nutrition-bag preparation and delivery, same-day delivery by 5:00 PM for other parenteral products, and documented experience with IV preparation, patient monitoring, and nutrition formulation adjustment. DOC anticipates awarding up to three contractors per region with an initial term running November 26, 2026 through June 30, 2030, firm pricing for the first two years, and set-aside goals favoring small (25%), minority-owned (10%), women-owned (6%), and veteran-owned (5%) businesses certified through Washington State agencies. Contractors must hold Washington State business licensure, pass NCIC clearance, and maintain specified commercial general liability, professional liability, business automobile, and cyber liability insurance. A second recent opportunity under the code—Seminole County, Florida IFB 60459723LAS, posted June 30, 2026—sought naloxone and drug deactivation systems, though this application falls outside the code's pharmaceutical-product nominal scope.

Recent activity is concentrated in the Pacific Northwest and Southeast, with Washington State corrections procurement driving the largest current solicitation. The Washington Department of Corrections is a primary repeat buyer under pharmaceutical and medical-supply codes serving correctional health systems. Geographic spread includes Washington State (most recent activity) and Florida, with no indication of broader multi-state solicitation patterns in the current opportunities block. Pricing structures are fixed-term in both opportunities, and both solicitations emphasize fast turnaround and reliability, with Washington DOC imposing strict delivery windows and penalties for late delivery. Set-aside participation is actively encouraged in the DOC solicitation through Washington State-certified minority, women-owned, and small-business designations.